Selective inhibitors of cyclooxygenase-2: Potential in elderly patients

Drugs and Aging

Volumn 9, Issue 6, 1996, Pages 406-417

  Davies, Neal M ^a   Wallace, John L ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTICOAGULANT AGENT; ANTIINFLAMMATORY AGENT; CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT;

AGED; COLON CANCER; DRUG USE; GASTROINTESTINAL SYMPTOM; HUMAN; INFLAMMATION; NONHUMAN; PAIN; PRIORITY JOURNAL; REVIEW; SIDE EFFECT;

EID: 0030449725     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-199609060-00004     Document Type: Review

References (124)

1. Wood PHN, Bradley EM. An epidemiological appraisal of bone and joint disease in the elderly. In: Wright V, editor. Bone and joint disease in the elderly. Edinburgh: Churchill Livingstone, 1982: 1-27
2. Patrono C. Aspirin as an antiplatelet drug. N Engl J Med 1994; 330: 1287-94
3. SALT Collaborative Group. Swedish Aspirin Low-Dose Trial (SALT) of 75mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. Lancet 1991; 338: 1345-9
4. Meyer JS, Rogers RL, McClintic K, et al. Randomised clinical trial of daily aspirin therapy in multi-infarct dementia. J Am Geriatr Soc 1989; 37: 549-55
5. Rogers J, Kirby LC, Hempelman SR, et al. Clinical trial of indomethacin in Alzheimer's disease. Neurology 1993; 43: 1609-11
6. Greenwald P. Colon cancer overview. Cancer 1992; 70: 1206-15
7. Koutsos MI, Shiff SJ, Rigas B. Can nonsteroidal anti-inflammatory drugs be recommended to prevent colon cancer in high risk patients? Drugs Aging 1995; 6: 421-5
8. Rosenberg L, Palmer JR, Zauber AG, et al. A hypothesis: non-steroidal anti-inflammatory drugs reduce the incidence of large bowel cancer. J Natl Cancer Inst 1991; 83: 355-8
9. Caradoc-Davies TH. Nonsteroidal anti-inflammatory drugs, arthritis, and gastrointestinal bleeding in elderly patients. Age Ageing 1984; 13: 295-8
10. Griffin MR, Ray WA, Schaffner W. Nonsteroidal anti-inflammatory drug use and death from peptic ulcer in elderly persons. Ann Intern Med 1988; 11: 359-63
11. Schlegel SI, Paulus HE. Nonsteroidal and analgesic therapy in the elderly. Clinics Rheum Dis 1986; 12: 245-73
12. Walt R, Katsehinski B, Logan R, et al. Rising frequency of ulcer perforation in elderly people in the United Kingdom. Lancet 1986; 1: 489-92
13. Hughes GRV. The problem of using NSAIDs in the elderly. Scand J Rheumatol 1991; 91 Suppl.: 19-25
14. Johnson AG, Day RO. The problems and pitfalls of NSAID therapy in the elderly (part 1). Drugs Aging 1991; 1: 130-43
15. Weinblatt ME. Nonsteroidal anti-inflammatory drug toxicity: increased risk in the elderly Scand J Rheumatol 1991; 91 Suppl.: 9-17
16. Jones AC, Berman P, Doherty M. Nonsteroidal anti-inflammatory drug usage and requirement in elderly acute hospital admissions. Br J Rheumatol 1992; 31: 45-8
17. Prichard PJ, Kitchingma GK, Walt RP. Human gastric mucosal bleeding induced by low dose aspirin, but not warfarin. BMJ 1989; 298: 493-6
18. Leivonen M, Sipponen P, Kivilaakso E. Gastric changes in coronary-operated patients with low dose aspirin. Scand J Gastroenterol 1992; 27: 912-6
19. Shorrock CJ, Langman MJS, Warlow C. Risks of upper GI bleeding during TIA prophylaxis with aspirin [abstract]. Gastroenterology 1992; 102: A165
20. Trujillo MA, Hardiner S, Garewal S, et al. Nonsteroidal anti-inflammatory agents in chemoprevention of colorectal cancer: at what cost? Dig Dis Sci 1994; 39: 2260-6
21. Duthie A, Nicholls A, Freeth M, et al. Fatal cholestatic jaundice in elderly patients taking benoxaprofen [letter]. BMJ 1982; 285: 62
22. Taggart S, Alderdice JM. Fatal jaundice in elderly patients taking benoxaprofen. BMJ 1982; 284: 1372
23. Armstrong CP, Blower AL. Nonsteroidal anti-inflammatory drugs and life threatening complications of peptic ulceration. Gut 1987; 28: 527-32
24. Guess HA, West R, Strand LM, et al. Fatal upper gastrointestinal hemorrhage or perforation among users of nonsteroidal anti-inflammatory drugs in Saskatchewan, Canada 1983. J Clin Epidemiol 1988; 41: 35-45
25. Soll AH, Winstein WM, Kurata J, et al. Nonsteroidal anti-inflammatory drugs and peptic ulcer disease. Ann Intern Med 1991; 114: 307-19
26. Cryer B, Redfern JS, Goldschmiedt M, et al. Effects of aging on gastric and duodenal mucosal prostaglandin concentrations in humans. Gastroenterology 1992; 102: 1118-23
27. Fries JF, Miller SR, Spitz PW, et al. Toward an epidemiology of gastropathy associated with nonsteroidal antiinflammatory drug use. Gastroenterology 1989; 96: 647-55
28. McCafferty DM, Granger DN, Wallace JL. Indomethacin-induced gastric injury and leukocyte adherence in arthritic versus healthy rats. Gastroenterology 1995; 109: 1173-80
29. Wallace JL. Gastric ulceration: critical events at the leukocyte-endothelium interface. Can J Physiol Pharmacol 1993; 71: 98-102
30. Andrews FJ, Malcontenti-Wilson C, O'Brien PE. Effect of non-steroidal antiinflammatory drugs on LFA-1 and ICAM-1 expression in the gastric mucosa. Am J Physiol 1994; 266: 657-64
31. Cush JJ, Rothlein R, Lindley HB, et al. Increased levels of circulating intercellular adhesion molecule 1 in the sera of patients with rheumatoid arthritis. Arthritis Rheum 1993; 36: 1098-102
32. Lamy PP. Renal effects of nonsteroidal antiinflammatory drugs: heightened risk in the elderly? J Am Geriatr Soc 1986; 34: 361-7
33. Blackshear JL, Davidman M, Stilmann MT. Identification of risk for renal insufficiency from nonsteroidal antiinflammatory drugs. Arch Intern Med 1983; 143: 1130-4
34. Patrono C, Dunn MJ. The clinical significance of inhibition of renal prostaglandin synthesis. Kidney Int 1987; 32: 1-12
35. Wilson TW, Frohlich JC, Carr K. Urinary prostaglandin E in patients with renal artery stenosis [letter]. Clin Res 1973; 21: 416
36. Mazanec DJ. Nonsteroidal anti-inflammatory drug therapy-clinical use in a high-risk group - the elderly. Cleve Clin J Med 1988; 55: 419-25
37. de Leeuw PW. Nonsteroidal anti-inflammatory drugs and hypertension: the risks in perspective. Drugs 1996; 51: 179-87
38. Kent RS, Kitchell BB, Shand DG, et al. The ability of vascular tissue to produce prostacyclin decreases with age. Prostaglandins 1981; 21: 483-90
39. Friedman PL, Brown Jr EJ, Gunther S, et al. Coronary vasoconstrictor effect of indomethacin in patents with coronary artery disease. N Engl J Med 1981; 305: 1171-5
40. Van den Ouweland FA, Gribnau FW, Meyboom RHB. Congestive heart failure due to nonsteroidal antiinflammatory drugs in the elderly. Age Ageing 1988; 17: 8-16
41. Goodwin JS, Regan M. Cognitive dysfunction associated with naproxen and ibuprofen in the elderly. Arthritis Rheum 1982; 25: 1013-5
42. Woodhouse KW, Wynne H. The pharmacokinetics of nonsteroidal anti-inflammatory drugs in the elderly. Clin Pharmacokinet 1987; 12: 111-2
43. Kean WF, Buchanan WW. Variables affecting the absorption of nonsteroidal anti-inflammatory drugs from the gastrointestinal tract. Jpn J Rheumatol 1987; 1: 227-44
44. Anne AP, Halpen SM, Streete PJ, et al. Slow release aspirin in the elderly. J R Soc Med 1994; 87: 183-4
45. Reidenberg MM. Drugs in the elderly. Bull N Y Acad Med 1980; 56: 703-14
46. Montamat SC, Cusack BJ, Vestal RE. Management of drug therapy in the elderly. Med Intell 1989; 321: 303-9
47. Tollesfsbol TO, Cohen JH. Role of protein molecular and metabolic aberrations in aging, in the physiologic decline of the aged, and in age-associated diseases. J Am Geriatr Soc 1986; 34: 282-94
48. Wallace SM, Verbeek RK. Plasma protein binding of drugs in the elderly. Clin Pharmacokinet 1987; 12: 41-72
49. Murray MD, Brater DC. Nonsteroidal anti-inflammatory drugs. Clin Geriatr Med 1989; 6: 365-97
50. Verbeek RK. Pharmacokinetics of drug interactions with non-steroidal anti-inflammatory drugs. Clin Pharmacokinet 1990; 19: 44-66
51. Buchanan WW, Kean WF. Implications of antirheumatic drug therapy in elderly patients with osteoarthritis. J Rheumatol 1978; 14: 98-100
52. Richardson CJ, Blocka KLN, Ross SG, et al. Effects of age and sex on piroxicam disposition. Clin Pharmacol Ther 1985; 37: 13-8
53. Arnoff GR, Ozawa T, De Sante KA, et al. Benoxaprofen kinetics in renal impairment. Clin Pharmacol Ther 1982; 32: 190-4
54. Woodhouse K. Drugs and the aging gut, liver and pancreas. Clin Gastroenterol 1985; 14: 863-81
55. Kelly JG, McGarry K, O'Malley K, et al. Bioavailability of labetalol increases with age. Br J Clin Pharmacol 1982; 14: 304-5
56. Piquette-Miller M, Jamali F. Effect of adjuvant arthritis on the disposition of acebutolol enantiomers in rats. Agents Actions 1992; 37: 290-6
57. Piquette-Miller M, Jamali F. Influence of severity of inflammation on the disposition kinetics of propranolol enantiomers in ketoprofen-treated and untreated adjuvant arthritis. Drug Metab Dispos 1995; 23: 240-5
58. Meffin PJ. The effects of renal dysfunction on the disposition of NSAIDs forming acyl-glucuronides. Agents Actions 1985; 17: 85-9
59. Verbeek RK. Pathophysiologic factors affecting the pharmacokinetics of nonsteroidal anti-inflammatory drugs. J Rheumatol 1988; 17: 44-57
60. Ritch AES, Perera WNR, Jones CJ. Pharmacokinetics of azapropazone in the elderly. Br J Clin Pharmacol 1982; 14: 116-9
61. Traeger A, Kunze M, Sten G, et al. Pharmacokinetics of indomethacin in the aged. Z Alternsforsch 1973; 27: 151-5
62. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature New Biol 1971; 231: 232-5
63. Wallace JL, Tigley AW. New insights into prostaglandins and mucosal defence. Aliment Pharmacol Ther 1995; 9: 227-35
64. Whittle BJR, Vane JR. A biochemical basis for the gastrointestinal toxicity of non-steroid anti-rheumatoid drugs. Arch Toxicol 1984; 7: 315-22
65. Meade EA, Smith WL, DeWitt DL. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1993; 268: 6610-4
66. Vane JR, Mitchell JA, Appleton I, et al. Inducible isoforms of cyclooxygenase and nitric-oxide synthetase in inflammation. Proc Natl Acad Sci U S A 1994; 91: 2046-50
67. Yamagata K, Andreasson KI, Kaufmann WE, et al. Expression of a mitogen-inducible cyclooxygenase in brain neurons: regulation by synaptic activity and glucocorticoids. Neuron 1993; 11: 371-86
68. Wallace JL. Mechanisms of non-steroidal anti-inflammatory drug (NSAID)-induced gastrointestinal damage: potential for development of gastrointestinal tract safe NSAIDs. Can J Physiol Pharmacol 1994; 72: 1493-7
69. Ehrlich GE, Katz WA, Cohen SA. Rheumatoid arthritis in the aged. Geriatrics 1970; 25: 103-13
70. Nesher G, Moore TL, Zucker J. Rheumatoid arthritis in the elderly. J Am Geriatr Soc 1991; 39: 284-94
71. Magaro M, Altamonte L, Zoli A, et al. Asymptomatic and symptomatic gastroduodenal patients affected by rheumatic disease treated with nonsteroidal anti-inflammatory drugs. Panminerva Med 1989; 31: 16-8
72. Sano HT, Hla JAM, Maier LJ, et al. In vivo cyclooxygenase expression in synovial tissue of patients with rheumatoid arthritis and osteoarthritis and rats with adjuvant and streptococcal cell wall arthritis. J Clin Invest 1992; 89: 97-108
73. Szcepanski A, Moatter T, Carley WW, et al. Induction of cyclooxygenase II in human synovial microvessel endothelial cells by interleukin-1: inhibition by glucocorticoids. Arthritis Rheum 1994; 37: 495-503
74. Crofford LJ, Wilder RL, Ristimalki AP, et al. Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissues. J Clin Invest 1994; 93: 1095-101
75. Gans KR, Galbraith W, Roman RJ, et al. Anti-inflammatory and safety profile of DuP697, a novel orally effective prostaglandin synthesis inhibitor. J Pharmacol Exp Ther 1990; 254: 180-7
76. Wong S, Lee SJ, Frierson MRI, et al. Antiarthritic profile of BF-389, a novel antiinflammatory agent with low ulcerogenic liability. Agents Actions 1992; 37: 90-8
77. Futaki N, Yoshikawa K, Hamasaka Y, et al. NS-398, a novel nonsteroidal anti-inflammatory drug with potent analgesic and antipyretic effects which cause minimal stomach lesions. Gen Pharmacol 1993; 24: 105-10
78. Boyce S, Chan CC, Gordon R, et al. L-745,337: a selective inhibitor of cyclooxygenase-2 elicits antinociception but not gastric ulceration in rats. Neuropharmacology 1994; 33: 1609-11
79. Masferrer JL, Zweifel BS, Manning PT, et al. Selective inhibition of inducible cyclooxygenase in vivo is anti-inflammatory and nonulcerogenic. Proc Natl Acad Sci USA 1994; 91: 3228-32
80. Seibert K, Zhung Y, Leaby K, et al. Pharmacological and biochemical demonstration of the role of cyclooxygenase-2 in inflammation and pain. Proc Natl Acad Sci USA 1994; 91: 12013-7
81. Tagari P, Pannetin M, Ragori R. Assessment of NSAID gastroenteropathy in primates [abstract]. Can J Physiol Pharmacol 1994; 7: 267
82. Appleton I, Tomlinson A, Willoughby DA. Inducible cyclooxygenase (COX-2): a safer therapeutic target? Br J Rheumatol 1994; 33: 410-1
83. Dingle JT. Prostaglandins in human cartilage metabolism. J Lipid Mediat 1993; 6: 303-12
84. Milner JC. Osteoarthritis of the hip and indomethacin [abstract]. J Bone Joint Surg 1971; 54B: 752
85. Ronningen H, Langeland N. Indomethacin treatment in osteoarthritis of the hip joint. Acta Orthop Scand 1979; 50: 169-74
86. Brooks PM, Potter SR, Buchanan WW. NSAID and osteoarthritis: help or hindrance? J Rheumatol 1982; 9: 3-4
87. Dingle JT. The interactions of cytokines, NSAIDs and prostaglandins in cartilage destruction and repair. Adv Prostaglandin Thromboxane Leukot Res 1990; 21: 955-65
88. Dingle JT. Cartilage maintenance in Osteoarthritis: interaction of cytokines, NSAIDs and proslaglandins in articular cartilage and repair. J Rheumatol 1991; 18 Suppl. 28: 30-7
89. Willoughby DA, Colville-Nash PR, Seed MD. Inflammation, prostaglandins, and loss of function. J Lipid Mediat 1993; 6: 287-93
90. Rashad S, Reuell P, Hemingway A, et al. Effect of nonsteroidal anti-inflammatory drugs on the course of osteoarthritis. Lancet 1989; 11: 519-22
91. Onoe Y, Miyaura C, Kaminakayashiki T, et al. IL-13 and IL-4 inhibit bone resorption by suppressing cyclooxygenase-2-dependent prostaglandin synthesis in osteoblasts. J Immunol 1996; 156: 758-64
92. Sato T, Morita I, Sakaguchi K, et al. Involvement of cyclooxygenase-2 in bone loss induced by interleukin-1. Adv Prostaglandin Thromboxane Leukot Res 1995; 23: 445-7
93. Harris RC, McKanna JA, Jacobson HR, et al. Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J Clin Invest 1994; 94: 2504-10
94. Dunn MJ, Staley RS, Hanson M. Characterization of prostaglandin production in tissue culture of rat renal medullary cells. Prostaglandins 1976; 12: 37-49
95. Persson AEG, Salomonsson M, Westerlund P. Macula densa cell function. Kidney Int 1991; 39 Suppl. 32: S39-44
96. Lagenbach R, Morham SG, Tiano HF, et al. Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell 1995; 83: 483-92
97. Morham SG, Langenbach RL, Loftin CD, et al. Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell 1995; 83: 473-82
98. Dinchuk JL, Car BD, Focht RJ, et al. Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II. Nature 1995; 378: 406-9
99. Wilborn J, Crofford LJ, Burdick MD, et al. Cultured lung fibroblasts isolated from patients with idiopathic pulmonary fibrosis have a diminished capacity to synthesize prostaglandin E2 and to express cyclooxygenase-2. J Clin Invest 1995; 95: 1861-8
100. Wallace JL. Cirino G. The development of gastrointestinal sparing nonsteroidal anti-inflammatory drugs. Trends Pharmacol Sci 1994; 15: 405-6
101. Graham DY, Malatry HM, Evans DG, et al. Epidemiology of Helicobacter pylori in an asymptomatic population in the United States: effect of age, race, and socioeconomic status. Gastroenterology 1991; 100: 1495-501
102. Katelaris PH, Scow F, Lin BP, et al. Effect of age, Helicobacter pylori infection, and gastritis with atrophy on serum gastrin acid secretion in healthy men. Gut 1993; 34: 11032-7
103. Safe AF, Warren B, Corfield A, et al. Helicobacter pylori infection in elderly people: correlation between histology and serology. Age Ageing 1993; 22: 215-20
104. Veldhuyzen van Zanten SJ, Pollack PT, Best LM, et al. Increasing prevalence of Helicobacter pylori infection with age: continuous risk of infection in adults rather than cohort effect. J Infect Dis 1994; 169: 434-7
105. Buckley M, Martin P, O'Morain C. Helicobacter pylori infection: implications for ulcer therapy in older patients. Drugs Aging 1994; 5: 1-7
106. Gebbers JO, Otto HF. Ulcerative colitis in the elderly. Lancet 1975; 11: 714-5
107. Levitan R, GI problems in the elderly: part II. Prevalent diseases and disorders. Geriatrics 1989; 44: 80-6
108. Kaufman HJ, Taubin HL. Nonsteroidal anti-inflammatory drugs activate quiescent inflammatory bowel disease. Ann Intern Med 1987; 107: 513-5
109. Davies NM. Toxicity of nonsteroidal anti-inflammatory drugs in the large intestine. Dis Colon Rectum 1995; 38: 1311-21
110. Fitzgerald GA. Mechanisms of platelet activation: thromboxane A2 as an amplifying signal for other agonists. Am J Cardiol 1991; 68: 11B-5B
111. Funk CD, Funk LB, Kennedy ME, et al. Human platelet/erythroleukemia cell prostaglandin G/H synthase: cDNA cloning, expression, and gene chromosomal assignment. FASEB J 1991; 5: 2304-12
112. Wallace JL, McKnight W, Del Soldato P, et al. Antithrombotic effects of a nitric oxide-releasing, gastric-sparing aspirin derivative. J Clin Invest 1945; 96: 2711-8
113. Tanaka A, Saki H, Motoyama Y, et al. Antiplatelet agents based on cyclooxygenase inhibition without ulcerogenesis: evaluation and synthesis of 4,5-bis (4-methoxyphenyl)-2-substituted thiazoles. J Med Chem 1994; 37: 1189-99
114. Davis AE, Patterson E. Aspirin reduces the incidence of colonic carcinoma in the dimethylhydrazine rat animal model. Aust N Z J Med 1994; 24: 301-3
115. Rao CV, Riverson A, Simi B, et al. Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal anti-inflammatory agent. Cancer Res 1995; 55: 1464-72
116. Craven PA, Saito R, DeRubertis FR. Role of local prostaglandin synthesis in the modulation of proliferative activity of rat colonic epithelium. J Clin Invest 1983; 72: 1365-75
117. Lupulescu A. Enhancement of carcinogenesis by prostaglandins. Nature 1978; 272: 634-6
118. Lynch NR, Castes M, Astoin M, et al. Mechanism of inhibition of tumour growth by aspirin and indomethacin. Br J Cancer 1978; 38: 503-12
119. Eberhardt CE, Colley RJ, Radhika A, et al. Up regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinonias. Gastroenterology 1994; 107: 1183-8
120. Kargman SL, O'Neill GP, Vikers PJ, et al. Expression of prostaglandin G/H synthase-1 and -2 protein in human colorectal cancer. Cancer Res 1991; 55: 2556-9
121. Ryseck RP, Raynoschek C, Macdonald-Bravo H, et al. Identification of an immediate early gene. PGHS B, whose protein product has prostaglandin synthase/cyclooxygenase activity. Cell Growth Differ 1993; 3: 443-50
122. Jones DA, Carlton DP, McIntyre TM, et al. Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines. J Biol Chem 1993; 268: 9049-54
123. Gierse JK, Hauser SD, Creely DP, et al. Expression and selective inhibition of the constitutive and in inducible forms of human cyclo-oxygenase. Biochem J 1995; 305: 479-84
124. Rochon PA, Fortin PR, Dear KBG, et al. Reporting of age data in clinical trials of arthritis. Arch Intern Med 1993; 153: 243-8